Clinical trials: Acute Myeloid Leukemia Refractory
AML, MDS
Study of APVO436 in Patients With AML or MDS
The primary objective of the Phase 1 part of the study is to determine the recommended dose of APVO436 administered intravenously to patients with AML or MDS.
- Trial name
- NCT03647800
- Testing
- APVO436
- Where
- 12 sites in United States
- Volunteers
- 136 people
- Sponsor
- Aptevo Research and Development LLC
Advanced Solid Tumor, Relapsed AML
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
This is an early phase clinical study using NEI-01 as single agent in oncology indication. This is an open label study and it's divided into two parts.
- Conditions
- Advanced Solid Tumor, Relapsed AML, Refractory AML
- Trial name
- NCT05226468
- Testing
- NEI-01
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- New Epsilon Innovation Limited
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer
- Trial name
- NCT05153330
- Testing
- BMF-219
- Where
- 41 sites in United States, Greece and 3 more
- Volunteers
- 55 people
- Sponsor
- Biomea Fusion Inc.
Acute Myeloid Leukemia
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Participants with AML that have gone into remission and come back (relapsed) or gone into remission with a number of leukemia cells still in their system (refractory) will be recruited for this study.
- Trial name
- NCT03552029
- Testing
- Quizartinib, Milademetan
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Daiichi Sankyo
Leukemia, Acute Myeloid (AML)
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who were refractory to or had relapsed after first-line…
- Trial name
- NCT02421939
- Testing
- gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine
- Where
- 126 sites in United States, Belgium and 12 more
- Volunteers
- 371 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Leukemia, Myeloid, Acute
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This is a single-arm, single-dose dose-escalation and dose-expansion study.
- Trial name
- NCT06118788
- Testing
- BG1805
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
The purpose of this study was to determine the safety and tolerability of gilteritinib given in combination with atezolizumab in participants with relapsed or treatment refractory FMS-like tyrosine kinase 3 (FLT3) mutated AML and…
- Trial name
- NCT03730012
- Testing
- gilteritinib, atezolizumab
- Where
- 12 sites in United States
- Volunteers
- 11 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Leukemia, Myelodysplastic Syndromes
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00070538
- Testing
- cytarabine, laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Multiple Myeloma, Non-Hodgkin Lymphoma
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
To determine the maximum tolerated dose (MTD) of OPB-51602
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT01344876
- Testing
- OPB-51602
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Hematologic Malignancies
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05104775
- Testing
- GNC-035
- Where
- 7 sites in China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Acute Myelogenous Leukemia
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
Primary objectives: To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose limiting toxicities (DLTs) in the proposed dose regimen To evaluate the pharmacokinetic (PK) profile of SAR103168…
- Trial name
- NCT00981240
- Testing
- SAR103168
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sanofi
Leukemia, Myeloid, Acute
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. In addition, acute myeloid leukemia patients who are in complete remission with high risk to relapse…
- Trial name
- NCT01690624
- Testing
- BI 836858
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Leukemia, Acute Myeloid Leukemia
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
This study is a phase Ib/II study of Max-40279-01 in combination with Azacitidine (AZA) in patients with Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
- Conditions
- Leukemia, Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05061147
- Testing
- MAX-40279-01
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Maxinovel Pty., Ltd.
Recurrent Adult Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to assess the safety of MEN1112, given as intravenous infusion, in patients with relapsed or refractory AML.
- Trial name
- ARMY (NCT02353143)
- Testing
- MEN1112
- Where
- 29 sites in Belgium, France and 3 more
- Volunteers
- 71 people
- Sponsor
- Menarini Group
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
The main purpose of this study is to test the safety and efficacy of VS-4718 in two types of leukemia patients and to find the right dose of VS-4718 for future clinical trials.
- Trial name
- NCT02215629
- Testing
- VS-4718
- Sponsor
- Verastem, Inc.
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
- Trial name
- NCT05961839
- Testing
- SGR-2921
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- Schrödinger, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the…
- Trial name
- AMpLify (NCT06128044)
- Testing
- CB-012
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- Caribou Biosciences, Inc.
Acute Myeloid Leukemia
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to understand the safety profile of LY2181308 sodium administered in combination with idarubicin and cytarabine to patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT00620321
- Testing
- LY2181308 sodium, cytarabine, idarubicin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS.
- Trial name
- AML (NCT02576301)
- Testing
- Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Mateon Therapeutics